Furosemide in Hyperkalemia Management

Clinical Context and Mechanism

Furosemide promotes potassium excretion in the urine by acting on the Na-K-2Cl receptors in the thick ascending limb of Henle's loop, and can be used to treat hyperkalemia in specific clinical contexts, particularly in cirrhotic patients with ascites or in non-acute hyperkalemia with adequate renal function 1, 2
The American Association for the Study of Liver Diseases recommends the use of furosemide in combination with spironolactone for the management of ascites in cirrhotic patients, with a suggested ratio of 100:40 mg 1, 2, 4, 5

Furosemide should be added to spironolactone monotherapy when hyperkalemia occurs in patients being treated for ascites, as recommended by the European Association for the Study of the Liver 1, 2, 3
The combination of spironolactone and furosemide maintains normokalemia while effectively managing ascites, with a significant reduction in the risk of hyperkalemia 1, 2, 4, 5

Furosemide is not a first-line treatment for acute, life-threatening hyperkalemia, but can be used in non-acute situations with adequate renal function 1, 2

The International Society of Nephrology recommends that furosemide not be used alone in severe hyperkalemia (>6.0 mmol/L) with ECG changes, and that significant renal impairment is a contraindication for its use 1, 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that furosemide be used with caution in patients with severe hypokalemia (<3 mmol/L) 4, 5, 6

The American College of Cardiology recommends frequent monitoring of serum potassium, creatinine, and sodium when using furosemide for hyperkalemia management, especially during the first weeks of treatment 1, 2, 6
The European Society of Cardiology recommends reducing or stopping aldosterone antagonists if severe hyperkalemia (>6 mmol/L) persists despite furosemide 1, 2, 3, 6